Science Explorer Interactive view Map
Company · Seattle · United States

CTI BioPharma (United States)

ctibiopharma.comROR OpenAlex
Research works
21
▼ 34% vs 2013–17
Citations
350
16.5 per fractional work
Top-10% rate
13.9%
record average 16.5%
Open access
37%
world 28%

Not ranked overall: CTI BioPharma (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 3.74× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 2.38× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 0.29× its world share, 0 worksPharmacology, Toxico…Computer Science: 0.33× its world share, 0 worksComputer ScienceEngineering: 0.61× its world share, 1 worksEngineeringHealth Professions: 0.66× its world share, 0 worksHealth ProfessionsMedicine: 3.06× its world share, 4 worksMedicineNursing: 7.07× its world share, 0 worksNursingEconomics, Econometrics and Finance: 0.86× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 7.1×. Every wedge is a field page.

Which keywords describe research at CTI BioPharma (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Prognostic Scoring System, JAK2 Mutation, Myelofibrosis, BCR-ABL, Imatinib, Prognostic Factors, Hematopoietic Stem Cells and Acute Myeloid Leukemia.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 10 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 10 words, with their numbers
  1. JAK2 Mutation6▲ 1249×1 topic
  2. Myelofibrosis6▲ 1249×1 topic
  3. Prognostic Scoring System6▲ 726×2 topics
  4. BCR-ABL3▲ 505×1 topic
  5. Imatinib3▲ 505×1 topic
  6. Prognostic Factors2▲ 19×3 topics
  7. Hematopoietic Stem Cells2▲ 71×2 topics
  8. AML1▲ 145×1 topic
  9. Acute Myeloid Leukemia1▲ 145×1 topic
  10. Cancer1▲ 3.4×5 topics

Which research topics does CTI BioPharma (United States) publish most on?

By volume in 2022–2025: Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, 3D Printing in Biomedical Research and Pluripotent Stem Cells Research.

Myeloproliferative Neopl…1Myeloproliferative Neoplasms: Diagnosis and Treatment: 1 fractional worksChronic Myeloid Leukemia…1Chronic Myeloid Leukemia Treatments: 1 fractional works3D Printing in Biomedica…03D Printing in Biomedical Research: 0 fractional worksPluripotent Stem Cells Research: 0 fractional worksVirus-based gene therapy research: 0 fractional worksCAR-T cell therapy research: 0 fractional worksTissue Engineering and Regenerative Medicine: 0 fractional worksMultiple Myeloma Research and Treatments: 0 fractional worksMelanoma and MAPK Pathways: 0 fractional worksNanowire Synthesis and Applications: 0 fractional works
GeneticsHematologyBiomedical EngineeringMolecular Biology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 1 works
  2. 2 Chronic Myeloid Leukemia Treatments Hematology 1 works
  3. 3 3D Printing in Biomedical Research Biomedical Engineering 0 works
  4. 4 Pluripotent Stem Cells Research Molecular Biology 0 works
  5. 5 Virus-based gene therapy research Genetics 0 works
  6. 6 CAR-T cell therapy research Oncology 0 works
  7. 7 Tissue Engineering and Regenerative Medicine Surgery 0 works
  8. 8 Multiple Myeloma Research and Treatments Hematology 0 works
  9. 9 Melanoma and MAPK Pathways Molecular Biology 0 works
  10. 10 Nanowire Synthesis and Applications Biomedical Engineering 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available37.3%not open62.7%

World: 28% of research is openly available.

with international co-authors45.9%domestic only54.1%

World: 19% is written across borders.

How has CTI BioPharma (United States)'s research output changed?

Output in 2018–2022 was 34% lower than in 2013–2017.

20152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Seattle

All research institutions in Seattle

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.